Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
NEUROLOGY 1996;47:889-894
© 1996 American Academy of Neurology

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

Experience during the first three years

Evidence of diminution of therapeutic efficacy in 35% of interferon beta-1b (IFNB)-treated multiple sclerosis (MS) patients who developed neutralizing antibodies (NABs) led to extensive study of the effects of NABs on therapeutic benefits, side effects, and magnetic resonance imaging (MRI) data. First, we validated the IFNB NAB assay used in the multicenter trial by having representative stored serum samples reanalyzed by an independent laboratory. When NABs developed (as defined), usually in the first year, the exacerbation rates after 18 months resembled placebo rates, the numbers of enlarging MRI lesions significantly increased compared with those in NAB-negative patients, and there was increased new lesion formation in the MRI (p = 0.067). However, worsening of the mean Expanded Disability Status Scale score in the 8-MIU treatment arm was higher in patients who remained NAB-negative in the third year (p = 0.083). NAB-positive patients were not overrepresented among the noncompleters, or in five patients having at least one episode of skin-site necrosis. After 18 months, flu-like symptoms were about twice as common in NAB-negative as in NAB-positive patients, although the frequency did not exceed 21% in any semester. Decisions to discontinue IFNB therapy should be made individually based on clinical response and a positive titer of NABs in the serum with the use of a reliable assay. ELISA and Western blot techniques measure binding antibodies, not NABs specifically, and are unsuitable for use. Possible, but as yet unproven, means of dealing with NAB positivity should be studied in properly designed trials. IFNB-1b remains an effective therapy for a majority (65%) of MS patients having relapses. The annual exacerbation rates in NAB-negative patients receiving the 8-MIU dosage regimen are about 50% of those seen in untreated patients, a greater reduction than the one-third reduction earlier reported for the entire high-dose arm, and a meaningful treatment benefit.

NEUROLOGY 1996;47: 889-894

Address correspondence and reprint requests to Dr. W.A. Sibley, University Hospital, Tucson, AZ 85724.




This article has been cited by other articles:


Home page
 NeurologyHome page
S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto
Predictive markers for response to interferon therapy in patients with multiple sclerosis
Neurology, March 25, 2008; 70(13_Part_2): 1119 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni
Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta
Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Sominanda, J Hillert, and A Fogdell-Hahn
In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 57 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
C. Boz, J. Oger, E. Gibbs, S.E. Grossberg, and the Neurologists of the UBC MS Clinic
Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study
Multiple Sclerosis, November 1, 2007; 13(9): 1127 - 1137.
[Abstract] [PDF]

Home page
 NeurologyHome page
P. A. Calabresi, G. Giovannoni, C. Confavreux, S. L. Galetta, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, P. W. O'Connor, J. T. Phillips, et al.
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
Neurology, October 2, 2007; 69(14): 1391 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Noronha
Neutralizing antibodies to interferon
Neurology, June 12, 2007; 68(24_suppl_4): S16 - S22.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
P. Sorensen, N. Koch-Henriksen, and K. Bendtzen
Are ex vivo neutralising antibodies against IFN-{beta} always detrimental to therapeutic efficacy in multiple sclerosis?
Multiple Sclerosis, June 1, 2007; 13(5): 616 - 621.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R. A Farrell and G. Giovannoni
Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis
Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J. Oger
Neutralizing antibodies and interferon treatment of multiple sclerosis: addressing the open questions
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 5 - 7.
[PDF]

Home page
 Mult SclerHome page
A. AL-Sabbagh
Neutralizing antibodies in MS therapy: reviewing the Rebif experience
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 8 - 13.
[Abstract] [PDF]

Home page
 Mult SclerHome page
S. E. Goelz and L. Walt
Development of neutralizing antibodies to intramuscular interferon beta-1a (Avonex (R))
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 14 - 20.
[Abstract] [PDF]

Home page
 Mult SclerHome page
F. Blanchette
Clinical significance of glatiramer acetate antibodies
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J. Oger and E. Gibbs
Binding antibodies: Vancouver's perspective
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 36 - 43.
[Abstract] [PDF]

Home page
 Mult SclerHome page
A.T. Reder
Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 53 - 62.
[Abstract] [PDF]

Home page
 NeurologyHome page
D. S. Goodin, E. M. Frohman, B. Hurwitz, P. W. O'Connor, J. J. Oger, A. T. Reder, and J. C. Stevens
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, March 27, 2007; 68(13): 977 - 984.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A Sominanda, U Rot, M Suoniemi, F Deisenhammer, J Hillert, and A Fogdell-Hahn
Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
Multiple Sclerosis, March 1, 2007; 13(2): 208 - 214.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al.
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients
Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737.
[Abstract] [PDF]

Home page
 Mult SclerHome page
B. Petersen, K. Bendtzen, N. Koch-Henriksen, M. Ravnborg, C. Ross, P. S. Sorensen, and The Danish Multiple Sclerosis Group
Persistence of neutralizing antibodies after discontinuation of IFN{beta} therapy in patients with relapsing-remitting multiple sclerosis
Multiple Sclerosis, June 1, 2006; 12(3): 247 - 252.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
S. J. Pittock, B. G. Weinshenker, J. H. Noseworthy, C. F. Lucchinetti, M. Keegan, D. M. Wingerchuk, J. Carter, E. Shuster, and M. Rodriguez
Not every patient with multiple sclerosis should be treated at time of diagnosis.
Arch Neurol, April 1, 2006; 63(4): 611 - 614.
[Full Text] [PDF]

Home page
 Mult SclerHome page
C Ross, K M Clemmesen, P S Sorensen, N Koch-Henriksen, and K Bendtzen
Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis
Multiple Sclerosis, February 1, 2006; 12(1): 39 - 46.
[Abstract] [PDF]

Home page
 Mult SclerHome page
D R Smith, B Weinstock-Guttman, J A Cohen, X Wei, C Gutmann, R Bakshi, M Olek, L Stone, S Greenberg, D Stuart, et al.
A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta
Multiple Sclerosis, October 1, 2005; 11(5): 573 - 582.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R. M Herndon, R. A Rudick, F. E Munschauer III, M. K Mass, A. M Salazar, M. E Coats, R. Labutta, J. R Richert, S. L Cohan, C. Genain, et al.
Eight-year immunogenicity and safety of interferon beta-1a-Avonex(R)treatment in patients with multiple sclerosis
Multiple Sclerosis, August 1, 2005; 11(4): 409 - 419.
[Abstract] [PDF]

Home page
 NeurologyHome page
G. Giovannoni and A. Goodman
Neutralizing anti-IFN-{beta} antibodies: How much more evidence do we need to use them in practice?
Neurology, July 12, 2005; 65(1): 6 - 8.
[Full Text] [PDF]

Home page
 NeurologyHome page
L. Kappos, M. Clanet, M. Sandberg-Wollheim, E. W. Radue, H. P. Hartung, R. Hohlfeld, J. Xu, D. Bennett, A. Sandrock, S. Goelz, et al.
Neutralizing antibodies and efficacy of interferon {beta}-1a: A 4-year controlled study
Neurology, July 12, 2005; 65(1): 40 - 47.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil
Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS
Neurology, July 12, 2005; 65(1): 48 - 55.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy
Neurology, July 12, 2005; 65(1): 33 - 39.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
T. Saida, K. Tashiro, Y. Itoyama, T. Sato, Y. Ohashi, Z. Zhao, and the Interferon Beta-1b Multiple Sclerosis Study Gr
Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study
Neurology, February 22, 2005; 64(4): 621 - 630.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. H. Stuart, S. Cohan, J. R. Richert, and A. Achiron
Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S19 - S27.
[Abstract] [Full Text]

Home page
 NeurologyHome page
T. K. Vartanian, S. S. Zamvil, E. Fox, and P. S. Sorensen
Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S42 - S49.
[Abstract] [Full Text]

Home page
 Mult SclerHome page
A J Petkau, G C Ebers, and A T Reder
Letter to the editor
Multiple Sclerosis, December 1, 2004; 10(6): 715 - 715.
[PDF]

Home page
 Mult SclerHome page
C Gneiss, M Reindl, A Lutterotti, R Ehling, R Egg, M Khalil, T Berger, and F Deisenhammer
Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity
Multiple Sclerosis, October 1, 2004; 10(5): 507 - 510.
[Abstract] [PDF]

Home page
 Mult SclerHome page
T L Vollmer, J T Phillips, A D Goodman, M A Agius, M A Libonati, J L Giacchino, and J S Grundy
An open-label safety and drug interaction study of natalizumab (AntegrenTM) in combination with interferon-beta (Avonex(R)) in patients with multiple sclerosis
Multiple Sclerosis, October 1, 2004; 10(5): 511 - 520.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
G Giovannoni
Is it time to consider rationalising IFN-{beta} treatment in individuals with multiple sclerosis?
J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1234 - 1234.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Bertolotto, A Sala, S Malucchi, F Marnetto, M Caldano, A Di Sapio, M Capobianco, and F Gilli
Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies
J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1294 - 1299.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto
Neutralizing antibodies reduce the efficacy of {beta}IFN during treatment of multiple sclerosis
Neurology, June 8, 2004; 62(11): 2031 - 2037.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
P. Rudge
Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis?
Multiple Sclerosis, April 1, 2004; 10(2): 123 - 125.
[PDF]

Home page
 Mult SclerHome page
A J. Petkau, R. A White, G. C Ebers, A. T Reder, W. A Sibley, F. D Lublin, D. W Paty, and IFNB Multiple Sclerosis Study Group
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
Multiple Sclerosis, April 1, 2004; 10(2): 126 - 138.
[Abstract] [PDF]

Home page
 Mult SclerHome page
M Clanet, L Kappos, H-P Hartung, R Hohlfeld, and The European IFNss-1a Dose-Comparison Study Invest
Interferon {beta}-1a in relapsing multiple sclerosis: four-year extension of the European IFN{beta}-1a Dose-C omparison Study
Multiple Sclerosis, April 1, 2004; 10(2): 139 - 144.
[Abstract] [PDF]

Home page
 NeurologyHome page
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland
Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients
Neurology, March 9, 2004; 62(5): 719 - 725.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert
Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs
Brain, February 1, 2004; 127(2): 259 - 268.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
H. H. Salama, J. Hong, Y. C. Q. Zang, A. El-Mongui, and J. Zhang
Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis
Brain, December 1, 2003; 126(12): 2638 - 2647.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Bendtzen
Anti-IFN BAb and NAb antibodies: A minireview
Neurology, November 11, 2003; 61(90095): S6 - 10.
[Full Text]

Home page
 NeurologyHome page
G. Giovannoni
Strategies to treat and prevent the development of neutralizing anti-interferon-{beta} antibodies
Neurology, November 11, 2003; 61(90095): S13 - 17.
[Abstract] [Full Text]

Home page
 NeurologyHome page
P. S. Sorensen
Antibodies to IFN-beta: The Danish National IFN-beta Project
Neurology, November 11, 2003; 61(90095): S27 - 28.
[Full Text]

Home page
 NeurologyHome page
M. Kremenchutzky
Long-term evolution of anti-INF{beta} antibodies in IFN{beta}-treated MS patients: The London, Canada, MS Clinic experience
Neurology, November 11, 2003; 61(90095): S29 - 30.
[Full Text]

Home page
 NeurologyHome page
A. J. Petkau
Statistical approaches to assessing the effects of neutralizing antibodies: IFN{beta}-1b in the pivotal trial of relapsing-remitting multiple sclerosis
Neurology, November 11, 2003; 61(90095): S35 - 37.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
N Lawrence, J Oger, T Aziz, J Palace, and A Vincent
A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN {beta}
J. Neurol. Neurosurg. Psychiatry, September 1, 2003; 74(9): 1236 - 1239.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
F. Casoni, E. Merelli, R. Bedin, A. Martella, A. Cesinaro, and A. Bertolotto
Necrotizing skin lesions and NA Bs development in a multiple sclerosis patient treated with IFN{beta} 1b
Multiple Sclerosis, August 1, 2003; 9(4): 420 - 423.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C Ortenzi, G Giovannoni, F Deisenhammer, and F E Munschauer
Neutralising antibodies to interferon {beta}
J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1162 - 1163.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. Bertolotto, F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R. L.P. Lindberg, R. Bottero, et al.
Persistent neutralizing antibodies abolish the interferon {beta} bioavailability in MS patients
Neurology, February 25, 2003; 60(4): 634 - 639.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
M Kob, J Harvey, F Schautzer, S Kascha, D Bibl, R Egg, M Reindl, T Berger, and F Deisenhammer
A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta
Multiple Sclerosis, February 1, 2003; 9(1): 32 - 35.
[Abstract] [PDF]

Home page
 NeurologyHome page
C. Polman, L. Kappos, R. White, F. Dahlke, K. Beckmann, C. Pozzilli, A. Thompson, J. Petkau, and D. Miller
Neutralizing antibodies during treatment of secondary progressive MS with interferon {beta}-1b
Neurology, January 14, 2003; 60(1): 37 - 43.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
C. Scagnolari, M. Casato, F. Bellomi, F. De Pisa, O. Turriziani, R. Coviello, M. R. Pirro, F. Dianzani, and G. Antonelli
Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia
Clin. Vaccine Immunol., January 1, 2003; 10(1): 70 - 77.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
S. A. Brod
Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity
Experimental Biology and Medicine, December 1, 2002; 227(11): 981 - 988.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
G Giovannoni, F E Munschauer 3rd, and F Deisenhammer
Neutralising antibodies to interferon beta during the treatment of multiple sclerosis
J. Neurol. Neurosurg. Psychiatry, November 1, 2002; 73(5): 465 - 469.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. L. Galetta, C. Markowitz, and A. G. Lee
Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review
Arch Intern Med, October 28, 2002; 162(19): 2161 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Bertolotto, S Malucchi, A Sala, G Orefice, P B Carrieri, M Capobianco, E Milano, F Melis, and M T Giordana
Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory
J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 148 - 153.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A J Coles
Neutralising antibodies to the beta interferons
J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 110 - 111.
[Full Text]

Home page
 NeurologyHome page
A.-M. Vallittu, M. Halminen, J. Peltoniemi, J. Ilonen, I. Julkunen, A. Salmi, J.-P. Eralinna, and the Finnish Beta-Interferon Study Group
Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients
Neurology, June 25, 2002; 58(12): 1786 - 1790.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
K. Bashir and J. N. Whitaker
Current Immunotherapy for Demyelinating Diseases
Arch Neurol, May 1, 2002; 59(5): 726 - 731.
[Full Text] [PDF]

Home page
 NeurologyHome page
P. A. Calabresi
Considerations in the treatment of relapsing-remitting multiple sclerosis
Neurology, April 23, 2002; 58(90084): S10 - 22.
[Abstract] [Full Text]

Home page
 NeurologyHome page
S. D. Cook, J. R. Quinless, A. Jotkowitz, and P. Beaton
Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients
Neurology, September 25, 2001; 57(6): 1080 - 1084.
[Abstract] [Full Text] [PDF]